The level of anti-topoisomerase I antibodies highly correlates with metacarpophalangeal and proximal interphalangeal joints flexion contractures in patients with systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 24, Issue 4, 2006, Pages 407-412

  Radić, Mislav ^a,b   Kaliterna, D Martinović ^a   Ljutic D ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b NONE   (Croatia)

Author keywords

Anti topoisomerase I antibody; Contracture; Systemic sclerosis

Indexed keywords

DNA TOPOISOMERASE ANTIBODY; ENZYME ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLEXION CONTRACTURE; GONIOMETRY; HAND RADIOGRAPHY; HUMAN; JOINT FUNCTION; METACARPOPHALANGEAL JOINT; PRIORITY JOURNAL; PROXIMAL INTERPHALANGEAL JOINT; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS;

ADULT; AGED; AUTOANTIBODIES; CONTRACTURE; DNA TOPOISOMERASES, TYPE I; FEMALE; FINGER JOINT; HAND; HUMANS; METACARPOPHALANGEAL JOINT; MIDDLE AGED; RANGE OF MOTION, ARTICULAR; SCLERODERMA, SYSTEMIC;

EID: 33748558430     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. LEROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatolog 1988; 15: 202-5.
2. KAHALEB MB: Vascular involvement in systemic sclerosis (SSc). Clin Exp Rheumatol 2004; 22 (3 Suppl. 33): S19-23.
3. TROJANOWSKA M: What did we learn by studying scleroderma fibroblasts? Clin Exp Rheumatol 2004; 22 (3 Suppl. 33): S59-63.
4. JANET POPE: Musculoskeletal involvement in scleroderma. Rheum Dis Clin N Am 2003; 23: 391-408.
5. MISRA R, DARTON K, JEWKES RF, BLACK CM, MAINI RN: Arthritis in scleroderma. Br J Rheumatol 1995; 34: 831-7.
6. HORIKI T, MORIUCHI J, TAKAYA M et al.: The coexistence of systemic sclerosis and rheumatoid arthritis in five patients. Clinical and immunogenetic features suggest a distinct entity. Arthritis Rheum 1996; 39: 152-156.
7. HO KT, REVEILLE JD: The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003; 5: 80-93.
8. STEEN VD, POWELL DL, MEDSGER TA JR: Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196-203.
9. WEINER ES, EARNSHAW WC, SENECAL J-L, BORDWELL B, JOHNSON P, ROTHFIELD NF: Clinical associations of anticentromere antibodies and antibodies to topoisomerase I: a study of 355 patients. Arthritis Rheum 1988; 31: 378-85.
10. FANNING GC, WELSH KI, BUNN C, DU BOIS R, BLACK CM: HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. Br J Rheumatol 1998; 37: 201-7.
11. KUWANA M, MEDSGER TA JR, WRIGHT TM: Detection of anti-DNA topoisomerase I antibody by an enzyme-linked immunosorbent assay using overlapping recombinant polypeptides. Clin Immunol Immunopatol 1995; 76: 266-78.
12. MOREL PA, CHANG HJ, WILSON JW et al.: Severe Systemic sclerosis with anti-topoisomerase I antibodies is associated with an HLA-DRwII allele. Hum Immumol 1994; 40: 101-10.
13. KUWANA M, KABURAKI J, MIMORI T, KAWAKAMI Y, TOJO T: Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000; 43: 1074-84.
14. SATO S, HAMAGUCHI Y, HASEGAWA M, TAKEHARA K: Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology (Oxford) 2001; 40: 1135-40.
15. HU PQ, FERTIG N, MEDSGER TA JR, WRIGHT TM: Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003; 48: 1363-73.
16. VALENTINI G, SILMAN AJ, VEALE D: Assessment of disease activity. Clin Exp Rheumatol 2003; 21: 39-41.
17. KAVANAUGH AF, SOLOMON DH, AND THE AMERICAN COLLEGE OF RHEUMATOLOGY AD HOC COMMITTEE ON IMMUNOLOGIC TESTING GUIDELINES: Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum 2002;47:546.
18. TAKEHARA K, MOROI Y, NAKABAYASHI Y, ISHIBASHI Y: Antinuclear antibodies in localized scleroderma. Arthritis Rheum 1983; 26: 612-6.
19. TAN EM, RODNAN GP, GARCIA I, MOROI Y, FRITZLER MJ, PEEBLES C: Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980; 23: 617-25.
20. BIZZARO, N, TONUTTI E, VILLALTA D et al.: Sensitivity and specifity of immunological methods for the detection of antitopoisomerase I (Sc1-70) autoantibodies: Results of a multicenter study. Clin Chem 2000; 46: 1681-5.
21. AMERICAN ACADEMY OF ORTHOPEDIC SURGEONS: Joint motion. Method of measuring and recording. Edinburgh: Churchill Livingstone, 1966: 5-7.
22. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revise criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
23. WEINER ES, EARNSHAW WC, SENECAL JL et al.: Clinical associations of anticentromere antibodies and antibodies to topoisomerase I: a study of 355 patients. Arthritis Rheum 1988; 31: 378-85.
24. HILDENBRANDT S, JACKH G, WEBER S, PETER HH: A long-term longitudinal isotypic study of anti-topoisomerase I autoantibodies. Rheumatol Int 1993; 12: 231-4.
25. VAZQUEZ-ABD D, RUSSELL CA, CUSICK SM, EARNSHAW WC, ROTHFIELD NF: Longitudinal study of anticentromere and antitopoisomerase-I isotypes. Clin Immunol 1995; 74: 257-70.
26. LA MONTAGNA G, SODANO A, CAPURRO V, MALESCI D, VALENTINI G: The arthropathy of systemic sclerosis: a 12 month prospective clinical and imaging study. Skeletal Radiol 2005; 34: 35-41.